AI in pharma is only as strong as the data beneath it, and pharmaceutical data is notoriously fragmented across R and D, clinical, and manufacturing silos. High-value AI depends on connecting heterogeneous sources: omics and assay data, structured and unstructured clinical data, real-world evidence from claims and EHRs, batch data from GxP-validated manufacturing lines, and lab systems. Each carries its own format, ontology, provenance, and integrity obligations. This playbook lays out how to assess data readiness for AI in pharma, harmonize across silos, establish lineage that satisfies ALCOA-plus, and build the governed data foundation every downstream model requires.
Fragmented data is the real bottleneck, not the algorithm
Ask any pharmaceutical data leader where AI programs stall and the answer is rarely the model. It is the data. A single molecule generates omics readouts, high-throughput screening results, and assay data in discovery; then case report forms, lab values, imaging, and adverse-event narratives in clinical development; then batch records, environmental monitoring, and instrument telemetry in manufacturing. These live in different systems, use different ontologies, and answer to different integrity regimes. Studies of enterprise AI repeatedly find that teams spend the majority of project time, often cited around 60 to 80 percent, on data preparation rather than modeling.
The fragmentation is structural, not accidental. Discovery data optimizes for experimental throughput, clinical data for regulatory submission, and manufacturing data for GxP traceability. Real-world data from claims and electronic health records arrives in yet another set of coding systems and completeness profiles. Without deliberate harmonization, an AI team cannot join a target to a trial outcome to a real-world safety signal. Data readiness, mapping ontologies, establishing lineage, and resolving integrity gaps, is therefore the foundational investment that every downstream use case, from discovery to pharmacovigilance, depends on. The mature pattern is to curate reusable feature stores and reference datasets for high-value target classes and therapeutic areas, so downstream discovery and clinical teams draw from vetted, harmonized inputs rather than re-extracting raw sources for every project and reintroducing the same integrity gaps each time.
Assess readiness source by source before building models
Score each data domain on accessibility, standardization, and integrity before committing it to an AI use case. The weakest dimension caps what the domain can support.
| Data domain | Readiness challenge | What good looks like |
|---|---|---|
| Omics and assay | High dimensionality, batch effects, inconsistent metadata | Harmonized pipelines, FAIR metadata, curated feature stores |
| Clinical trial | Mixed structured and unstructured, CDISC variance, silos by study | Standardized to common data model, coded terminologies, linked |
| Real-world data | Claims and EHR coding gaps, incomplete follow-up, privacy limits | Mapped to OMOP or similar, quality-profiled, de-identified |
| Manufacturing and QC | Instrument silos, proprietary formats, GxP integrity scope | Contextualized historian, validated pipelines, full lineage |
| Lab and LIMS | Fragmented instruments, manual transcription, weak provenance | Automated capture, ALCOA-plus lineage, harmonized units |
Build the governed data foundation before the model layer
- Run a source-by-source readiness audit scoring accessibility, standardization, and integrity, and refuse to greenlight a use case whose weakest required domain is not ready.
- Adopt shared data standards and common data models, such as CDISC for clinical and OMOP for real-world data, so sources become joinable rather than perpetually reconciled by hand.
- Establish end-to-end data lineage from source system through transformation to model input, satisfying ALCOA-plus for any data feeding a regulated decision.
- Contextualize manufacturing and lab data by connecting historians, LIMS, and instruments into a governed layer with validated pipelines rather than exporting to spreadsheets.
- Treat de-identification, consent scope, and privacy constraints on real-world and clinical data as design inputs, building access controls and provenance in from the start rather than retrofitting them after a model is built.
Data mistakes that sink pharma AI
- Jumping to modeling before harmonization, then burning the majority of the project on ad hoc data wrangling that cannot be reused across use cases.
- Ignoring provenance and lineage, so a model that works cannot be defended in an audit because the data cannot be reconstructed to ALCOA-plus standards.
- Underestimating real-world data quality gaps, treating claims and EHR data as clean and complete when coding gaps and lost follow-up bias every downstream inference.
- Leaving manufacturing and lab data trapped in proprietary instrument silos, so quality and yield models never get the contextualized signal they need.
Measure whether your data foundation is AI-ready
- Share of priority data domains mapped to a common data model and available through a governed, queryable layer.
- Data-preparation time as a fraction of total project time, targeting steady decline as harmonization and feature stores mature.
- Percentage of model-input datasets with complete, reconstructable lineage meeting ALCOA-plus.
- Data-quality scores, completeness, coding accuracy, and follow-up integrity, for real-world and clinical sources feeding models.
Frequently asked questions
Why do pharma AI projects spend so much time on data?
Because pharmaceutical data is fragmented across discovery, clinical, and manufacturing silos, each with different formats, ontologies, and integrity regimes. Teams commonly spend 60 to 80 percent of project time on preparation. Investing in harmonization and common data models up front converts that recurring cost into reusable foundation.
What common data models should we adopt?
Use CDISC standards for clinical data and OMOP for real-world data such as claims and EHRs, plus FAIR metadata practices for omics. Common models make heterogeneous sources joinable so you can link a target to a trial outcome to a real-world safety signal without endless manual reconciliation.
How does data lineage relate to compliance?
Any data feeding a regulated decision must meet ALCOA-plus, meaning it is attributable, complete, and reconstructable. End-to-end lineage from source through transformation to model input is what lets you defend an AI output in an inspection, so build it before, not after, deploying models.
Related reading
Go deeper on this sector and topic.